The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLC [0.03%]
肿瘤突变负荷，免疫相关不良事件和小细胞肺癌中免疫检查点抑制剂疗效的关系初探
Alessio Cortellini
Alessio Cortellini
Novel MRPL13-ALK and PPP1CB-ALK Double Fusion As a Potential Mechanism of Acquired Resistance to First-Line Osimertinib in EGFR-Mutant High-Grade Neuroendocrine Tumor of the Lung [0.03%]
新型MRPL13-ALK和PPP1CB-ALK双重融合可能是EGFR突变的肺高级别神经内分泌肿瘤对一线奥希替尼产生获得性耐药的潜在机制
Yuyan Jiao,Ming Liu,Ningning Luo et al.
Yuyan Jiao et al.
Development and Validation of Diffuse Idiopathic Pulmonary Neuroendocrine Hyperplasia Diagnostic Criteria [0.03%]
弥漫性特发性肺神经内分泌增生诊断标准的制定与验证
Olga Sazonova,Venkata Manem,Chloé Béland et al.
Olga Sazonova et al.
Introduction: Diffuse idiopathic pulmonary neuroendocrine hyperplasia (DIPNECH) is a rare condition that is likely underdiagnosed owing to the lack of established and validated diagnostic criteria. These clinical guidelin...
Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population [0.03%]
帕博利珠单抗在真实世界澳大利亚恶性间皮瘤患者中应用的回顾性评估
Tamkin Ahmadzada,Wendy A Cooper,Mikaela Holmes et al.
Tamkin Ahmadzada et al.
Introduction: We investigated the efficacy and toxicity of pembrolizumab in patients with mesothelioma from a real-world Australian population. We aimed to determine clinical factors and predictive biomarkers that could h...
Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC [0.03%]
免疫相关不良事件与SCLC中程序性细胞死亡蛋白1/程序性死亡配体1阻断的临床结果之间的关联
Biagio Ricciuti,Abdul Rafeh Naqash,Jarushka Naidoo et al.
Biagio Ricciuti et al.
Introduction: The development of immune-related adverse events (irAEs) has been associated with improved efficacy of immune checkpoint inhibitors in patients with urothelial cancer, melanoma, and NSCLC. Whether this assoc...
Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a Patient With MET Exon 14-Mutant NSCLC [0.03%]
克里唑蒂尼耐药后MET第14外显子突变的非小细胞肺癌患者使用卡马替尼对软脑膜疾病的治疗反应
Paola Cravero,Nuno Vaz,Biagio Ricciuti et al.
Paola Cravero et al.
Katsuhiro Masago,Katsutoshi Seto,Shiro Fujita et al.
Katsuhiro Masago et al.
Introduction: The aim of this study is to evaluate the clinical backgrounds, including driver mutations, of those patients with early stage NSCLC who experienced recurrence beyond 5 years after complete resection. ...
Multiple Brain Pseudoprogression in a Patient With NSCLC Treated With Pembrolizumab [0.03%]
接受Pembrolizumab治疗的NSCLC患者出现多发脑假性进展
Laura Moliner,Jaume Capellades,Álvaro Taus et al.
Laura Moliner et al.
Yen-Ting Lin,Jin-Yuan Shih
Yen-Ting Lin
Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial [0.03%]
来自SAFIR02-Lung试验的晚期NSCLC中的体细胞和生殖细胞BRCA 1和2突变
Jordi Remon,Benjamin Besse,Alexandra Leary et al.
Jordi Remon et al.
Introduction: Molecular profiling is considered a standard of care in advanced NSCLC. A comprehensive next-generation sequencing panel can discover somatic or germline BRCA1/2 mutations that are new druggable molecular al...